LSBio Acquires Absolute Antibody Ltd.
22.12.2020 12:00:00 EET | Business Wire | Press release
LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast. Terms of the transaction were not disclosed.
LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The Company has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.
Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications.
“We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies,” said Dr. Heather Holemon, CEO of LSBio. “It provides an opportunity to offer more to our customers by adding their recombinant antibody production and engineering capabilities as well as their highly complementary product portfolio. This transaction aligns with our goal of providing researchers access to what they are asking for as far as superior consistency and better validation.”
“We are delighted to be joining forces with the LSBio team,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Absolute Antibody was founded with a vision to make engineered recombinant antibodies accessible to all, and we have grown rapidly as the demand for recombinant antibody technology has increased. That vision remains and working with LSBio enables us to continue growing both the recombinant antibody catalog and our custom services, while still delivering the highest level of product quality and customer satisfaction.”
The acquisition marks the latest investment by LSBio to rapidly build its product portfolio. In 2019, LSBio acquired both Nordic-MUbio and Everest Biotech to strengthen the Company’s offering of proprietary monoclonal and polyclonal antibodies. All LSBio companies currently retain their independent names, websites and employees, with the entire family of companies owned by St. Louis-based private equity firm Thompson Street Capital Partners.
Absolute Antibody, Ltd. were advised by Pivotal Scientific Limited, a specialist Mergers and Acquisitions business based in Oxford, UK & Clark Holt, a specialist law firm based in Swindon UK.
About LSBio
LSBio (www.lsbio.com) enables researchers by providing a variety of antibodies and research reagents. Previous acquisitions of Nordic-MUbio and Everest Biotech have strengthened the company’s offering of proprietary monoclonal and polyclonal antibodies. The continued emphasis for LSBio has been on building the portfolio and coupling that with application-specific antibody validation. Through ongoing in-house testing, over 15,000 of the LSBio antibodies have been identified as exceptional IHC reagents and given the IHC-plus™ brand. LSBio itself was acquired by Thompson Street Capital Partners (TSCP) in 2018.
About Absolute Antibody
Absolute Antibody (www.absoluteantibody.com) was founded in 2012, with the vision to make engineered recombinant antibodies available to all. The company offers antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of engineered recombinant antibodies. Absolute Antibody customers include leading pharmaceutical, biotechnology and diagnostics companies, as well as academic researchers in more than 60 different countries worldwide.
About Kerafast
Kerafast, Inc. (www.kerafast.com) is a reagent company whose primary mission is to make unique laboratory-made research tools easily accessible to the global scientific community. Since its founding in 2011, Kerafast has partnered with more than 190 academic research institutions internationally and provided reagents to scientists in 63 countries across six continents. In 2018, Kerafast merged with Absolute Antibody, a company specializing in recombinant antibody technology, to further improve the selection of research tools available to the scientific community.
About TSCP
Thompson Street Capital Partners is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. TSCP has acquired more than 150 companies in the Healthcare & Life Science Services, Software & Technology Services and Business Services & Engineered Products sectors and have managed more than $2.6 billion since being founded in 2000. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005100/en/
Contact information
Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Announces 2026 Western Europe NIQ BASES Breakthrough Innovation Award Winners21.10.2026 11:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the winners of its 2026 Western Europe NIQ BASES Breakthrough Innovation Awards, recognizing the most successful and commercially impactful product innovations launched across Great Britain, France, Germany, Italy, and Spain. Now in its annual Western Europe edition, the NIQ BASES Breakthrough Innovation Awards celebrate products that have demonstrated exceptional market performance, sustained consumer demand, and meaningful category impact. Winners were selected using NIQ's comprehensive view of innovation performance, leveraging proprietary retail measurement, consumer panel, and BASES innovation analytics to identify launches that achieved strong early success and continued momentum. This year's winners reveal an innovation landscape shaped by evolving consumer expectations around health, convenience, premiumization, sustainability, and experience. While breakthrough ideas emerged across a wide range of
Reply Introduces Reply Immersive Experience: a Space Where Artificial Intelligence and Immersive Technologies Bring Multisensory Brand Experiences to Life21.10.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] introduces Reply Immersive Experience, a multisensory smart room that combines artificial intelligence and immersive technologies to create environments where audiences can explore products, interact with digital scenarios and take part in stories that unfold in the space around them. Images, sound, lighting and settings transform in real time, adapting to the experience and audience interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021483868/en/ Reply introduces Reply Immersive Experience, a multisensory smart room that combines artificial intelligence and immersive technologies to create environments where audiences can explore products, interact with digital scenarios and take part in stories that unfold in the space around them. The first format, AQUA by Christian Mandura, debuts on 21 October 2026 as part of Buonissima in Turin, with a six-act performance combining fine dining, artif
Kanadevia Completes World’s First Technology Demonstration Plant in the Waste to Energy Sector to Advance Decarbonization21.10.2026 11:00:00 EEST | Press release
Kanadevia Corporation (TOKYO:7004) has been developing High-CO₂-Concentration Waste Incineration Technology since FY2024. The project aims to separate and capture carbon dioxide (CO₂) from flue gas generated during waste incineration. Kanadevia will begin the world's first demonstration of this technology in the Waste to Energy sector at the Shinagawa Incineration Plant in Shinagawa City, Tokyo, in November 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021372259/en/ Conceptual Diagram of the Technology The demonstration project aims to commercialize an innovative technology for the efficient capture of CO₂ from waste-incineration flue gas. The demonstration facility, which serves as a pilot-scale plant, comprises an incinerator capable of processing 2 tons of waste per day and a CO₂ separation and capture system. By replacing combustion air with oxygen and recirculated flue gas, the technology increases the CO₂ con
Arini Announces Final Close of Inaugural Direct Lending Fund, Targeting Over $4 Billion of Deployment21.10.2026 10:00:00 EEST | Press release
Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related vehicles are targeting deployment of over $4 billion, including anticipated leverage, making it among the largest debut European direct lending funds ever raised. Arini has built a sizeable initial portfolio throughout the fundraise, focusing on senior secured loans to borrowers demonstrating recurring and underwritable cash flow profiles and operating in industries with limited risk of disruption. Total deployment for the strategy is now approaching $2 billion across a range of sectors and geographies, alongside founder-led, family-owned and sponsor-backed businesses. This scale of deployment, in conjunction with Arini’s highly selective underwriting standards, demonstrates the depth of the European middle market opportunity set. Unlike in the US, banks in Europe have a dominant market share in corpor
Skechers Wins Major Victory Against Kizik in Patent Infringement Suit21.10.2026 10:00:00 EEST | Press release
Skechers U.S.A., Inc. (“Skechers”), the third largest footwear company in the world and leader in hands-free footwear technology, announced today that it won a major legal and commercial victory in a patent infringement lawsuit filed by Fast IP, LLC (“Kizik”) against Skechers before the Unified Patent Court (“UPC”) in Munich. Skechers, the market leader in hands-free footwear, sells thousands of styles of hands-free shoes worldwide under its Slip-ins and Swift Fit trademarks. In 2025, Kizik sued Skechers at the UPC for alleged patent infringement involving four of its thousands of hands-free styles. Skechers won on three of the four styles, with the fourth being a minor and commercially insignificant style for Skechers. In its ruling, the Munich Court stated that Kizik’s infringement claims are “largely unfounded.” Skechers’ leading hands-free footwear position globally is the result of its product innovation, transforming the century-old idea of hands-free footwear into a true modern
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom